Introduction {#s1}
============

Severe combined immunodeficiency (SCID) refers to a heterogeneous group of primary immunodeficiency disorders characterized by impaired T lymphocyte development with an effect on the B cell and NK cell number and/or function. SCID pathogenesis involves multiple genes whose defect which leads to abnormal cellular and humoral immune responses. Affected children suffer from recurrent infections, notably infections with opportunistic organisms such as *Pneumocystis jiroveci*, chronic diarrhea, failure to thrive and persistent mucocutaneous candidiasis ([@B1]). SCID is not apparent at birth and the presence of maternally derived antibodies provide some protection in the initial few months which further delays the diagnosis. As a consequence, these children also get the routine administration of live vaccines which is known to be contraindicated in SCID patients. Diagnosis of SCID is supported by a low absolute lymphocyte counts, abnormalities in lymphocyte subpopulations, absent/reduced naïve T cell population and recent thymic emigrants, absent T cell receptor excision circles (TRECs) and a low or absent T cell response to mitogens.

The Primary Immune Deficiency Treatment Consortium (PIDTC) classifies patients into Typical SCID with total T cell (CD3) count of \<300 cells/microL ([@B2]). Depending on the B and NK cell status, patients are further classified as T^−^B^+^NK^−^, T^−^B^+^NK^−^, T^−^B^−^NK^+^, T^−^B^−^NK^−^. Some patients can have T cells (leaky/atypical SCID) which are mostly oligoclonal and are classified as T^+^ or T^++^ SCID. These modify the counts from T^−^B^−^NK^−^ to T^+^B^−^NK^−^,T^−^B^+^NK^−^ to T^+^B^+^NK^−^, from T^−^B^−^NK^+^ to T^+^B^−^NK^+^, or from T^−^B^+^NK^+^ to T^+^B^+^NK^+^ ([@B3]).

More than 30 genes are involved in SCID pathogenesis ([@B3]). Despite a wide genetic heterogeneity, patients are clinically indistinguishable. Importantly, the clinical features in SCID infants can also be found in patients with human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome (AIDS). Hence, it is essential to rule out such secondary causes of lymphopenia by determining the presence of maternal HIV antibodies and measuring the levels of HIV by polymerase chain reaction (PCR).

With the exception of common gamma chain cytokine receptor (IL2RG) deficiency which follows X-linked pattern of inheritance, all the other causes are inherited in an autosomal recessive pattern. There are many SCID cases where the genetic defect is still unknown. In countries with a low rate of consanguinity, approximately 50% of all SCID cases are X-linked ([@B4]). Of the AR forms of SCID, 20--30% of all SCID patients are T^−^, B^−^, NK^+^, and approximately half of these patients have mutations in the *RAG1* or *RAG2* genes.

The incidence of SCID was previously reported at approximately 1 in 100,000 but the implementation of TREC assay for Newborn screening of SCID revealed the true incidence of SCID to be 1 in 58,000 live births (95% CI, 1 in 46,000--1 in 80,000) for typical SCID, leaky/atypical SCID, and Omenn syndrome ([@B5]). SCID is a fatal disorder and without treatment, death from infection usually occurs within the first 2 years of life. Diagnosis must be made before severe life-threatening infections occur so that the immunity can be restored with enzyme replacement or Hematopoietic Stem Cell Transplantation (HSCT); early transplantation (before 3.5 months of age) can lead to long-term survival ([@B6]). Gene therapy is an alternative option available especially for patients with ADA-SCID and X-SCID.

Here, we report the first largest series on the clinical, immunological, and molecular findings in SCID patients (*n* = 57) from India.

Materials and Methods {#s2}
=====================

Patients and Samples
--------------------

Patients (*n* = 57) suspected of Severe combined immunodeficiency (SCID) at National Institute of Immunohaematology (NIIH) between 2013 and 2018 were included in the study. Informed consent for participating in the study was procured from the family members in accordance with the declaration of Helsinki and 3 mL peripheral blood was collected in EDTA, Plain and Heparin vacutainers each. The study was approved by the Institutional Ethics Committee of NIIH.

A clinical proforma was filled for all patients which included the age, consanguinity, family history, clinical parameters like number of infections, site of infections, age of presentation, failure to thrive, diarrhea, presence of any skin rashes, administration of vaccines and post live vaccine complications, presence of dysmorphic features, hepatosplenomegaly, lymphadenopathy.

Prenatal diagnosis (PND) was provided to a total of four affected families. Two families were provided a molecular confirmation of the genetic defect on the chorionic villus sample. Maternal contamination was ruled out by Kleihauer-Betke (KB) staining and analysis of the variable number of tandem repeats (VNTR) using the apolipoprotein B (*ApoB)*, ACTB2, D1S80, and *IgJH* genes. Phenotypic prenatal diagnosis was provided to 2 families on the Fetal cord blood (FB) sample (1--2 mL, \<0.5% of expected weight in all cases) as molecular diagnosis was not available at the time of PND. The FB sample was collected at 18 weeks of gestation by ultrasound-guided cordocentesis after procuring informed consent from the parents. The FB sample accepted for analysis had a high MCV value (\>110 fL) with narrow and single red cell distribution curve. The testing was performed within 3 h of sampling.

Immunological Workup
--------------------

Initial investigations involved a complete blood cell count (CBC) on a Sysmex XS-800i (Sysmex Co., Cobe, Japan) 5-part automated hematological analyzer, lymphocyte subset analysis by flow cytometry using BD Multitest 6-color TBNK reagent followed by acquisition of cells on FACS Aria I; analysis was performed on FACS Diva and FlowJo software (BD Biosciences, San Jose, CA, USA). Serum immunoglobulin levels were estimated by nephelometry (BNProspec, Siemens).

The percentage of naïve and memory T cell subsets on CD4^+^ and CD8^+^ cells was measured by flow cytometry using anti-CD45RA phycoerythrin (PE), anti-CD45RO Phycoerythrin/Cy7 (PE-Cy7) and anti-CD62L allophycocyanin (APC) procured from BD Biosciences, San Jose, CA, USA.

T cell receptor excision circles (TRECs) were measured by an in-house modification of a previously described method ([@B7]).

Flow cytometric evaluation of Human Leukocyte antigen- D related (HLA-DR) expression on lymphocytes and monocytes using cell surface markers specific for T cells (anti-CD3 Peridinin-chlorophyll-protein Complex: CY5.5 Conjugate, PerCP-Cy5), B cells (anti-CD19 allophycocyanin \[APC\]), monocytes (anti-CD14 Phycoerythrin \[PE\]) and HLA-DR (anti-HLA-DR fluorescein isothiocyanate \[FITC\]) was performed.

T cell proliferation assay was performed using CellTrace Violet dye (Thermo Fisher Scientific). The PBMCs separated from the heparinized blood samples of the patients was suspended in complete RPMI medium (GIBCO, USA) containing 10% fetal calf serum (GIBCO, USA) and was stained at a density of 106 cells with Cell trace violet (1 μM) for 20 min at 37°C. The cells were aliquoted into 96 well tissue culture plates at a density of 105 cells per well and stimulated with phytohemagglutinin (PHA) (1 μg/ml) and cultured for 72 h. Flow cytometric analysis of T cell functionality was assessed on CD3^+^ and CD69^+^ (activation marker) T cells.

Clonality of the T cell receptor (TCR) was assessed by flow cytometric evaluation of TCR-Vβ repertoire by using the IOTest® Beta Mark.

Flow cytometric evaluation of CD132 expression on B cells was done using cell surface markers specific for B cells (anti-CD19 allophycocyanin \[APC\]) and CD132 (Phycoerythrin \[PE\]) procured from Biolegend. Flow cytometric evaluation of CD127 on T cells was done using cell surface markers specific for T cells (anti-CD3 fluorescein isothiocyanate \[FITC\]) and anti-CD127 allophycocyanin \[APC\]) procured from BD biosciences.

Phospho-STAT5 analysis was performed on whole blood after IL-2 (10 μg/ml) (Peprotech, NJ, USA) stimulation for 15 min at 37°C. The cells were fixed with BD Lyse Fix and permeabilized with Perm III Buffer. The cells were stained with anti-phospho-STAT5 (p-STAT5) Alexa 488 (Y694, clone 47, BD Biosciences) according to the manufacturer\'s instructions.

Determination of Adenosine deaminase (ADA) activity on RBC lysate was performed by the Giusti and Galant calorimetry method using a commercially available kit (ADA-MTB kit) from Tulip Diagnostics, India.

Data was presented in terms of median and percentages. One-way analysis of variance (ANOVA) test was used for comparison of \>2 groups. Mann-Whitney U-test was used for comparing groups with non-parametric data. The *p*-values less than 0.05 were considered statistically significant. All statistical calculations were done using GraphPad prism (Chicago, IL, USA) version 15 for Microsoft Windows.

Molecular Investigations
------------------------

Molecular investigations were done by Sanger sequencing of *IL2RG, ADA, RAG1, RAG2, IL7RA, ZAP70* genes using the standard protocol. Targeted Next Generation sequencing was performed using a custom capture kit by Medgenome Labs Pvt Ltd. India, in samples where molecular diagnosis was not identified by Sanger Sequencing. The libraries were sequenced on Illumina sequencing platform (mean coverage \>80 to 100X). The identified mutations were confirmed by Sanger sequencing.

Results {#s3}
=======

Patient Characteristics and Clinical Findings
---------------------------------------------

In this study, a total of 57 SCID patients were diagnosed and followed up. Forty patients (70%) were male. Data on the status of consanguinity was available for 53 cases, from which 19 patients (36%) belonged to consanguineous parents. A positive family history of SCID was recorded in 32 families (56%). The median age at onset and diagnosis of all patients referred with a clinical suspicion of SCID was 60 days (range, 12--304) and 152 days (range, 12--730), respectively. Two patients received a pre-symptomatic diagnosis in view of strong family history.

The most common clinical manifestations were pneumonia (66%), failure to thrive (60%), chronic diarrhea (35%), gastrointestinal infection (21%), oral candidiasis (21%) and BCGiosis (12%). In our cohort, organisms isolated included both gram- negative and gram-positive bacterium: *Staphylococcus aureus* (*n* = 2), *Klebsiella pneumonia* (*n* = 8), *Pseudomonas aeruginosa* (*n* = 4), *Burkholderia* (*n* = 1), *Chryseobacterium* (*n* = 1). Viral organisms isolated included rotavirus (*n* = 1), cytomegalovirus (CMV) (*n* = 2), Rubella (*n* = 1), RSV (*n* = 1), Varicella (*n* = 1). Fungal infections included PCP (*n* = 1). Other features such as Erythematous skin rash was observed in 29% of the cases, Dysmorphism was seen in 8% cases, abscess in 8% and Hepatosplenomegaly in 3% cases. [Table 1](#T1){ref-type="table"} presents the clinical findings in our patient cohort.

###### 

Clinical findings in SCID patients.

  **Pt. code**   **Genetic defect**        **Sex**   **Age at diagnosis (Days)**   **Age of onset (Days)**   **Family history**   **Consanguinity**   **Pneumonia**   **GI infection**   **Organism isolated (source)**                **Oral candidiasis**   **Chronic diarrhea**   **FTT**   **BCGiosis**    **Skin rash**   **Dysmorphic features**   **Other infections**                                                                                      **Status**
  -------------- ------------------------- --------- ----------------------------- ------------------------- -------------------- ------------------- --------------- ------------------ --------------------------------------------- ---------------------- ---------------------- --------- --------------- --------------- ------------------------- --------------------------------------------------------------------------------------------------------- ------------------------
  P1             *PNP*                     Female    365                           15                        \+                   \+                  \+              --                 *Candida* (Blood culture)                     \+                     --                     \+        --              --              --                        Meningitis, delayed motor milestones and involuntary movements                                            Dead/18 months of age
  P2             *RAG1 (OS)*               Female    91                            46                        --                   \+                  --              --                 --                                            --                     \+                     --        --              \+              --                        Blephatis, Shedding of eyelashes, ear discharge, discharge from umbilical stump                           Dead/4 months of age
  P3             *RFXAP*                   Male      183                           183                       \+                   --                  \+              --                 *Burkholderia cepacia* (Blood culture)        --                     --                     \+        --              \+              --                        Amoeboid blanching skin rash                                                                              Dead/7 months of age
  P4             *ADA* (Leaky/atypical)    Male      183                           20                        \+                   \+                  \+              --                 --                                            --                     --                     \+        --              --              \+                        Low set ears, frontal bossing, fused eyebrows                                                             Dead/6 months of age
  P5             *ZAP70*                   Male      365                           61                        \+                   \+                  \+              \+                 --                                            --                     \+                     --        \+              \+              --                        NS                                                                                                        Dead/18 months of age
  P6             *RFXAP*                   Male      91                            91                        \+                   --                  --              --                 --                                            --                     --                     --        --              --              --                        Pre-symptomatic diagnosis                                                                                 HSCT/Dead at 7 months
  P7             *IL2RG*                   Male      61                            61                        \+                   --                  --              --                 --                                            --                     --                     --        --              --              --                        Umbilical sepsis, fever, urinary tract infection                                                          Dead/5 months of age
  P8             *IL2RG*                   Male      91                            ND                        ND                   ND                  \+              ND                                                                                      ND                     ND        ND              ND              ND                        NS                                                                                                        Dead/6 months of age
  P9             *IL2RG*                   Male      91                            91                        --                   --                  --              --                 *Pseudomonas aeruginosa* (Blood culture)      --                     --                     --        --              --              --                        Multiple deep-seated abscess                                                                              Dead/5 months of age
  P10            *IL2RG*                   Male      152                           30                        \+                   --                  \+              --                 *Klebsiella pneumonia* (Blood culture)        \+                     --                     \+        --              \+              --                        Oral thrush, convulsion,                                                                                  Dead/11 months of age
  P11            *ADA*                     Male      30                            45                        \+                   --                  \+              --                 *Klebsiella* (Blood culture)                  --                     --                     \+        ND              \+              --                        Hypoglycemic convulsions, blisters on face and cheeks and hyperpigmentation                               Dead/2 months of age
  P12            *JAK3* (Leaky/atypical)   Male      183                           122                       \+                   --                  \+              \+                 *Staphylococcus aureus* (Blood culture)       --                     \+                     \+        \+              --              --                        Soft hepatosplenomegaly                                                                                   HSCT/Dead at 12 months
  P13            *AK2*                     Male      12                            12                        \+                   \+                  \+              --                 *Candida* (Blood culture)                     \+                     --                     --        NI              --              --                        NS                                                                                                        HSCT/Dead at 2 months
  P14            *ADA*                     Female    76                            30                        \+                   --                  \+              \+                 --                                            --                     \+                     \+        --              --              --                        NS                                                                                                        Dead/3 months of age
  P15            *JAK3*                    Male      61                            15                        --                   --                  --              --                 --                                            --                     --                     --        --              --              --                        Recurrent boils, multiple scalp abscess and liver abscess, liver abscess                                  Dead/6 months of age
  P16            *RAG1*                    Female    753                           365                       --                   --                  --              \+                 *Candida* (Blood culture)                     \+                     \+                     --        --              --              --                        Oesophagul candidiasis, celiac disease                                                                    Alive
  P17            *ADA*                     Male      152                           137                       \+                   --                  --              --                 --                                            --                     --                     --        \+              --              --                        Humerus crack with severe swelling at site for 3-5, hepatosplenomegaly with soft tissue mass in abdomen   Dead/5 months of age
  P18            *RAG2*                    male      122                           122                       --                   --                  \+              \+                 *Rotavirus* (stool culture)                   --                     \+                     \+        --              \+              --                        Atopic dermatitis, Impetigo over back                                                                     Dead/6 months of age
  P19            *-* (Leaky/atypical)      Male      365                           122                       --                   --                  \+              \+                 *Gram+ve Bacilli*                             --                     \+                     \+        --              --              --                        Pallor                                                                                                    Dead/2 months of age
  P20            *RFX5*                    Female    213                           91                        --                   --                  \+              --                 *Candida* (Bronchoalveolar lavage)            --                     --                     --        --              --              --                        Fever, hepatosplenomegaly, motor development delay                                                        HSCT/Dead at 9 months
  P21            *RFXAP*                   Male      122                           15                        \+                   \+                  \+              \+                 *Candida albicans* (Bronchoalveolar lavage)   \+                     \+                     \+        --              \+              --                        NS                                                                                                        Dead/6 months of age
  P22            *ADA*                     Male      30                            15                        \+                   --                  --              --                 *Klebsiella pneumonia* (Blood culture)        \+                     --                     \+        --              \+              --                        NS                                                                                                        Dead/1.5 months of age
  P23            --                        Male      213                           46                        \+                   ND                  \+              \+                 *ND*                                          --                     \+                     \+        --              --              --                        Tachypnea with respiratory distress, acute bronchiolitis                                                  Dead/7 months of age
  P24            *RAG2*                    Male      213                           152                       --                   --                  \+                                 *Klebsiella pneumonia* (Blood culture)        --                     --                     --        --              --              --                        NS                                                                                                        Dead/12 months of age
  P25            *PRKDC* (leaky)           Male      61                            61                        \+                   \+                  \+              --                 *RSV* (ND)                                    --                     --                     \+        --              --              \+                        low set ears, retrognathia Developmental delay                                                            Lost to follow up
  P26            *RAG1* (Leaky/atypical)   Male      730                           91                        \+                   \+                  --              --                 --                                            --                     \+                     --        --              \+              --                        Nephrotic range of proteinuria,ITP                                                                        Dead/36 months of age
  P27            --                        Female    91                            30                        \+                   --                  \+              --                 *Pseudomonas aeruginosa* (Blood culture)      --                     --                     --        --              \+              --                        extensive pyoderma                                                                                        Dead/6 months of age
  P28            --                        Male      304                           304                       --                   ND                  --              --                 *Klebsiella* (Blood culture)*, Candida*       \+                     --                     \+        --              --              --                        Hyponatremia, septic shock, severe dehydration                                                            Dead/12 months of age
  P29            *JAK3*                    Female    152                           106                       --                   --                  \+              --                 *AFB* (Blood culture)                         \+                     --                     \+        \+              --              --                        NS                                                                                                        Dead/8 months of age
  P30            --                        female    61                            61                        --                   \+                  \+              --                 --                                            \+                     --                     \+        --              --              --                        Developmental delay, diffuse cerebral atrophy, microcephaly, scalp seborrhea, oral thrush                 Lost to follow up
  P31            *IL7RA*                   Female    213                           61                        --                   \+                  \+              --                 *PCP* (ND)                                    \+                     \+                     --        --              --              --                        Convulsions                                                                                               Dead/8 months of age
  P32            *DCLER1C*                 Male      183                           152                       \+                   --                  \+              --                 *Pseudomonas aeruginosa* (Blood culture)      --                     --                     --        Not immunized   --              --                        Acute respiratory distress                                                                                Died/7 months of age
  P33            *CIITA*                   Male      213                           122                       --                   --                  --              --                 *Chryseobacterium* (Blood culture)            --                     --                     --        --              --              --                        Acute respiratory distress                                                                                Alive
  P34            -- (Leaky/atypical)       Female    243                           213                       \+                   ND                  \+              --                 *Candida* (Blood culture)                     \+                     --                     --        ND              --              --                        Acute fever, positive for H1N1                                                                            Lost to follow up
  P35            *RAG2* (Leaky/atypical)   Female    243                           91                        --                   --                  \+              --                 --                                            --                     --                     \+        ND              --              --                        NS                                                                                                        Dead/10 months of age
  P36            *JAK3*                    Male      183                           61                        \+                   \+                  \+              --                 --                                            --                     \+                     \+        --              --              \+                        Triangular face, low set ears, dry skin, hair sparse                                                      Dead/6 months of age
  P37            *IL2RG*                   Male      91                            91                        \+                   --                  \+              --                 --                                            --                     --                     \+        --              \+              --                        Recurrent fever, hypopigmented fungal perianal rashes                                                     Dead/4 months of age
  P38            *RAG1*                    Female    122                           61                        \+                   --                  --              \+                 --                                            --                     \+                     \+        --              --              \+                        \- Microcephaly, short philtrum, broad nasal bridge                                                       Lost to follow up
  P39            *JAK3* (OS)               Female    122                           30                        --                   --                  --              --                 *MTB* (Sputum culture)                        --                     --                     --        --              \+              --                        Culture negative sepsis, cutaneous abscess, rectovaginal fistula                                          Dead/5 months of age
  P40            *JAK3*                    Male      152                           15                        --                   --                  --              --                 *Budding yeast with Pseudohyphae* (ND)        --                     \+                     \+        \+              \+              --                        NS                                                                                                        Dead/6 months of age
  P41            *IL2RG*                   Male      213                           122                       \+                   --                  \+              --                 *Disseminated BCG* (ND)                       --                     --                     --        \+              --              \+                        Abscess                                                                                                   Dead/9 months of age
  P42            *RAG1*                    Male      60                            60                        \+                   --                  \+              \+                 --                                            --                     \+                     \+        --              --                                        NS                                                                                                        Dead/3 months of age
  P43            *RAG2* (OS)               Male      122                           183                       \+                   --                  \+              --                 *Klebsiella pneumonia* (Blood culture)        --                     \+                     \+        --              \+              --                        NS                                                                                                        Dead/6 months of age
  P44            *IL2RG* (Leaky)           Male      152                           0                         --                   --                  --              --                 --                                            --                     --                     --        --              --              --                        Pre-symptomatic diagnosis                                                                                 Dead/10 months of age
  P45            *IL2RG*                   Male      183                           106                       --                   --                  \+              --                 --                                            --                     --                     \+        --              --              --                        persistent cough, hypoxia, and respiratory distress                                                       Dead/8 months of age
  P46            *DCLER1C*                 Male      183                           183                       \+                   --                  --              --                 --                                            --                     --                     \+        --              --              --                        Fever high grade of unknown origin                                                                        Dead/8 months of age
  P47            --                        Male      18                            18                        \+                   --                                                                                                   --                                                                      --              --                        NS                                                                                                        Alive
  P48            *RAG*                     Male      27                            20                        --                   --                  \+              --                 *Pseudomonas aeruginosa* (Blood culture)      --                     --                     --        --              --              --                        Pallor, fever, cough                                                                                      Dead/months of age
  P49            *RFXANK*                  Female    243                           122                       \+                   \+                  \+              --                 --                                            --                     --                     \+        --              --              --                        NS                                                                                                        Dead/10 months of age
  P50            *ZAP70* (Atypical)        Male      304                           304                       \+                   \+                  \+              \+                 *Cryptosporidium, AFB* (ND)                   --                     \+                     \+        \+              \+              --                        Bilateral axillary lymphadenopathy, erythematous Urticarial rash                                          Dead/3 months of age
  P51            *RAG1* (OS)               Female    46                            5                         \+                   --                  --              --                 *Staph aureus* (Blood culture)                --                     --                     \+        --              \+              --                        Erythematous scaly eczema like rash, inguinal lymphadenopathy                                             Dead/3 months of age
  P52            *JAK3*                    Male      91                            183                       --                   \+                  \+              \+                 *Klebsiella pneumonia* (Blood culture)        --                     \+                     \+        --              --              --                        NS                                                                                                        Alive
  P53            *ADA*                     Male      61                            14                        --                   \+                  \+              --                 *Rubella, HSV* (ND)                           --                     --                     \+        --              --              --                        Severe sepsis increased respiratory activity                                                              Alive
  P54            *JAK3*                    Female    304                           15                        \+                   \+                  \+              --                 *Candida* (Blood culture)                     \+                     ND                     \+        ND              ND              ND                        ND                                                                                                        Dead/11 months of age
  P55            *JAK3* (Leaky/atypical)   Male      122                           30                        --                   \+                  \+              --                 --                                            --                     \+                     \+        --              --              --                        NS                                                                                                        Alive
  P56            --                        Female    61                            61                        \+                   \+                  \+              --                 --                                            --                     --                     \+        --              --              --                        NS                                                                                                        Dead/3 months of age
  P57            *RAG1*                    Male      304                           10                        --                   \+                  \+              --                 --                                            --                     \+                     \+        --              \+              --                        Recurrent fever Septic arthritis, Knee abscess                                                            Dead/10 months of age

*ND, No data; "+," Present; "--," Absent; NS, Nothing significant; HSCT, Hematopoietic stem cell transplantation; RSV, respiratory syncytial virus; BCG, Bacillus Calmette--Guérin; HSV, herpes simplex virus; MTB, mycobacterium tuberculosis; IL2RG, Interleukin 2 receptor gamma chain; JAK3, Janus Kinase 3; IL7RA, Interleukin 7 receptor alpha; ADA, Adenosine Deaminase; PNP, Purine nucleoside phosphorylase; AK2, adenylate kinase 2; RAG1/2, Recombination activating gene1/2; DCLER1C, DNA Cross-Link Repair 1C; RFXAP, Regulatory Factor X Associated Protein; RFX5, Regulatory factor 5; RFXANK, Regulatory Factor X Associated Ankyrin Containing Protein; CIITA, Class II Major Histocompatibility Complex Transactivator; ZAP70, Zeta-chain-associated protein kinase 70*.

Immunological Findings
----------------------

Based on the Primary Immune Deficiency Treatment Consortium (PIDTC) case definition for SCID, 38 of 57 patients (67%) with absent or severely low T cell counts (\<300 cells/μL) were classified as typical SCIDs ([@B2]). The remaining patients were classified as Leaky/Atypical SCIDs. Lymphopenia (\<2,500 lymphocyte counts/μL) was noted in 36 of 57 (63%) patients including both typical and atypical SCID cases. Of these, the median lymphocyte count/μL was 680 (11--2,403) counts/μL. Classification of patients based on comparison of absolute counts/μL of B and NK cells with age matched reference ranges ([@B8]) revealed 14 patients with T^−^B^+^NK^−^ phenotype (25%), 2 patients as T^−^B^+^NK^+^ (3.5%), 10 as T^−^B^−^NK^−^ (17.5%), 12 patients with T^−^B^−^NK^+^ SCID (21%).

7 of 57 (12%) cases were identified with isolated T cell lymphopenia (selective deficiency of CD4^+^ T cells (*n* = 6) or CD8^+^ T cells (*n* = 1) and were eventually grouped under the category "Combined Immunodeficiency (CID) generally less profound than Severe combined Immunodeficiency" according to the IUIS classification ([@B9]).

The remaining cases with detectable T cells were classified as leaky/atypical SCID (12 cases, 21%). Of these cases, 6 patients had T^+^B^+^NK^−^ phenotype (1 Omenn phenotype), 2 patients as T^+^B^+^NK^+^, 1 as T^+^B^−^NK^−^, 3 patients with T^+^B^−^NK^+^ SCID (1 Omenn phenotype).

The median T cell counts/μL in typical SCIDs was significantly lower than leaky SCID (1\[range, 0--388\] vs. 1,165 \[range, 493--8,288\]; *p* \< 0.0001) and CID (1,565 \[range, 927--13,900\]; *p* \< 0.0001).

Though the median ALC/μL was significantly lower in the SCID group (including typical and leaky SCID) than CID (771 \[11--9,570\] counts/μL vs. 4,408 \[2,860--1,9041\] counts/μL; *p* = 0.0003), the median age of onset in the SCID group (46 \[range, 0--730\] days) was not statistically significant from the median age of onset within CID group (106 days \[range, 15--304\], *p* = 0.08).

Apart from lymphocyte subset analysis, serum immunoglobulin levels were measured in a total of 41 available patient serum samples. The median serum IgG level in all SCID subtypes was lower than the age matched ranges. However, 14 patients had normal Sr. IgG levels in our cohort. These included 6 cases of B^+^ SCID, 7 cases of B^−^ SCID, and 1 case of ZAP70 deficiency. Eight of these Fourteen patients were less than 6 months of age, suggesting the presence of maternal immunoglobulins in these children. Normal IgE was observed in 7 cases (1 case of B^+^ SCID, 2 cases of B^−^SCID, 4 patients with T^−^B^−^NK^+^) and elevated IgE was noted in 2 cases (T^−^B^+^ SCIDs).

[Table 2](#T2){ref-type="table"} presents the basic immunological findings in our patient cohort.

###### 

Immunological findings in SCID patients.

  **Patient code**   **Genetic defect**        **WBC/μL**   **P(%)**   **L(%)**   **M(%)**   **E(%)**   **ALC/μl**   **B%**   **Abs counts/μL**   **T%**   **Abs counts/μL**   **Th%**   **Abs counts/μL**   **Tc%**   **Abs counts/μL**   **NK%**   **Abs counts/μL**   **IgG g/L**   **IgA g/L**   **IgM g/L**   **IgE IU/ml**
  ------------------ ------------------------- ------------ ---------- ---------- ---------- ---------- ------------ -------- ------------------- -------- ------------------- --------- ------------------- --------- ------------------- --------- ------------------- ------------- ------------- ------------- ---------------
  P1                 *PNP*                     38200        92         2          6          0          364          42       153                 32       116                 30        109                 2         7                   17        62                  8.19          1.75          2.17          ND
  P2                 *RAG1 (OS)*               14870        19         21         1          59         3123         0        0                   11       344                 3         94                  5         156                 82        2561                1.41          0.249         .179          15.3
  P3                 *RFXAP*                   14300        76         20         3          1          2860         59       1687                38       1087                8.5       243                 29        829                 2         57                  ND            ND            ND            ND
  P4                 *ADA* (Leaky/atypical)    12850        84         6          10         0          771          3        23                  85       655                 34        262                 38        293                 11        85                  2.64          0.56          0.3           28
  P5                 *ZAP70*                   28850        23         66         5          6          19041        12       2285                73       13900               73        13900               0         0                   15        2856                6.18          1.48          1.7           \<4.4
  P6                 *RFXAP*                   5700         54         39         0          7          3078         48       1477                48       1477                11        339                 35        1077                3         92                  ND            ND            ND            ND
  P7                 *IL2RG*                   7020         32         43         12         13         3019         97       2928                1.7      51                  0.7       21                  1         30                  1         30                  2.7           0.2           0.04          5.3
  P8                 *IL2RG*                   5750         42         48         10         0          2760         95       2622                0.1      3                   0         0                   0.1       3                   3.2       88                  ND            ND            ND            ND
  P9                 *IL2RG*                   17810        72         15         10         3          2672         82       2191                0        0                   0         0                   0         0                   12        321                 1.54          0.235         0.302         735
  P10                *IL2RG*                   5390         81         14         6          ND         710          98       695.8               0        0                   0         0                   0         0                   0         0                   0.564         1.37          0.231         61.7
  P11                *ADA*                     12240        90         1          9          0          160          0        0                   0        0                   0         0                   0         0                   1         2                   ND            ND            ND            ND
  P12                *JAK3* (Leaky/atypical)   16370        50         32         6          13         5238         68       3562                26       1362                6         314                 19        995                 1         52                  ND            ND            ND            ND
  P13                *AK2*                     570          4          44         33         0          251          29       73                  0        1                   0         0                   0         0                   41        103                 7.37          0.343         0.92          ND
  P14                *ADA*                     11000        ND         0.1        ND         ND         11           0        0                   0        0                   0         0                   0         0                   0         0                   ND            ND            ND            ND
  P15                *JAK3*                    34000        80         11         9          0          4752         95       4514                0        0                   0         0                   0         0                   2         95                  ND            ND            ND            ND
  P16                *RAG1*                    3530         52         36         7          5          1280         42       537.6               34       435.2               2         25.6                18        230.4               17        217.6               10.8          0.239         2.34          ND
  P17                *ADA*                     6490         90         1          8          0          80           0        0                   0        0                   0         0                   0         0                   100       80                  1.41          0.32          0.12          ND
  P18                *RAG2*                    9980         93         1          4          2          91           0        0                   1        1                   0         0                   0         0                   98        89                  0.226         0.239         0.168         \<4.45
  P19                -- (Leaky/atypical)       10500        25         70         4          1          7350         13       956                 42       3087                6         441                 26        1911                8         588                 3.1           1.08          1.97          ND
  P20                *RFX5*                    5750         10         62         26         2          3565         36       1283                26       927                 6         214                 16        570                 36        1283                0.641         0.17          4.32          17.3
  P21                *RFXAP*                   5630         11         64         23         1          3610         43       1549                44       1585                19        685                 19        685                 9         324                 ND            ND            ND            ND
  P22                *ADA*                     8220         38         10         39         13         822          0        0                   0        0                   0         0                   0         0                   0.1       13                  ND            ND            ND            ND
  P23                --                        8300         90         2          7          0          130          4        7                   2        3                   0         0                   0         0                   89        148                 ND            ND            ND            ND
  P24                *RAG2*                    7020         74         7.4        12         2.1        491          0        0                   0.2      1                   0.1       0                   0.1       0                   99        486                 2.14          0.42          0.93          43.7
  P25                *PRKDC (leaky)*           7900         72         17         11         0          1343         47       631                 50       672                 22        295                 28        376                 2         27                  ND            ND            ND            ND
  P26                *RAG1* (Leaky/atypical)   8910         72         19         9          0          1693         38       643                 43       728                 22        372                 8         135                 13        220                 ND            ND            ND            ND
  P27                --                        20600        87         3          9          1          714          98       700                 0.5      4                   0.4       0                   0         0                   1         7                   0.75          0.01          0.5           0.1
  P28                --                        7990         89         2          9          0          160          0.1      0                   1        2                   0.5       1                   0.5       1                   14        22                  3.11          0.358         0.17          107
  P29                *JAK3*                    17720        94         5          2          0          886          93       823                 0        0                   0         0                   0         0                   0         0                   0.13          0.06          0.14          ND
  P30                --                        1500         21         65         12         ND         315          0        0                   0        0                   0         0                   0         0                   100       315                 1.69          0.239         0.168         17.8
  P31                *IL7RA*                   5420         61         20.3       17         0.7        1100         86       946                 0        0                   0         0                   0         0                             152                 0.07          0.06          0.2           2
  P32                *DCLER1C*                 21470        73         10         15.2       2          1232         0        0                   1        9                   0.3       4                   0.2       2                   99        1220                1.4           0.06          0.04          2
  P33                *CIITA*                   11780        30         57         7          6          6750         75       5036                23       1544                8         537                 13        873                 1         47                  0.0683        0.316         4.32          17.3
  P34                --(Leaky/atypical)        6700         ND         41         ND         ND         2800         32       879                 29       797                 3         82                  4         110                 19        522                 0.037         0.249         0.239         ND
  P35                *RAG2* (Leaky/atypical)   4900         40         40         20         0          1940         1        18                  65       1165                7         125                 31        556                 14        251                 11.2          0.3           1.87          ND
  P36                *JAK3*                    5460         82         6          11         0.2        328          92       301                 0        0                   0         0                   0         0                   0         0                   0.336         0.246         0.172         \<4.45
  P37                *IL2RG*                   3610         44         14         38         3          510          90       455                 0        0                   0         0                   0         0                   0.5       3                   3.96          0.246         0.172         \<4.45
  P38                *RAG1*                    2440         46         22         31         0          537          0        0                   0        0                   0         0                   0         0                   90        483                 ND            ND            ND            ND
  P39                *JAK3* (OS)               19200        60         33         7          0          6330         35       2218                63       3992                11        697                 53        3558                0         0                   0.936         0.239         0.255         \<4.45
  P40                *JAK3*                    41130        89         8          3          0          3250         99       3275                0        0                   0         0                   0         0                   0         0                   0.878         0.239         0.168         \<4.45
  P41                *IL2RG*                   3470         88         7          1          4          240          98       238                 1        2                   1         2                   0         0                   0         0                   0.33          0.45          0.06          ND
  P42                *RAG1*                    2500         96         3          1          0          75           0        0                   0        0                   0         0                   0         0                   99        74                  ND            ND            ND            ND
  P43                *RAG2* (OS)               13660        9          3          0          28         1250         0        ND                  29       357                 17        209                 8         98                  43        529                 1.85          0.314         0.217         163
  P44                *IL2RG (Leaky)*           7870         73         19         8          0          1495         65       972                 33       493                 8         120                 24        359                 1         15                  12.9          0.843         2.07          976
  P45                *IL2RG*                   4580         73         15         12         ND         700          98       671                 0        0                   0         0                   0         0                   1         3                   0.048         0.02          0.015         0
  P46                *DCLER1C*                 7930         62         9          29         0          710          0        0                   0        0                   0         0                   0         0                   99        709                 0.0976        0.239         0.168         4.45
  P47                --                        11550        46         25         9          17         2930         39       1126                4        116                 4         116                 0         0                   54        1559                ND            ND            ND            ND
  P48                *RAG*                     4550         93         5          1          1          210          0        0                   0        0                   0         0                   0         0                   3         6                   ND            ND            ND            ND
  P49                *RFXANK*                  7770         4          67         23         5          5240         12       625                 61       3176                34        1770                25        1301                26        1354                0.94          0.239         0.975         17.8
  P50                *ZAP70 (Atypical)*        11240        27         56         15         2          6270         8        504                 89       5602                42        2644                46        2895                1         63                  2.2           0.6           0.216         ND
  P51                *RAG1* (OS)               17400        38         55         7          0          9570         0        0                   85       8288                ND        ND                  ND        ND                  8         780                 0.179         0.001         0.08          19.8
  P52                *JAK3*                    16170        93         3          4          0.1        485          90       437                 0        0                   0         0                   0         0                   2.2       10                  8.98          1.51          1.8           17.8
  P53                *ADA*                     3800         52         18         29         1          680          55       376                 35       239                 15        103                 22        150                 6         41                  4.68          0.239         0.168         4.45
  P54                *JAK3*                    11500        ND         18         ND         ND         2403         99.6     2393                0.3      7                   0         0                   0         0                   0         0                   1.35          0.25          0.19          0.1
  P55                *JAK3* (Leaky/atypical)   9270         47         41         11         0.4        3801         37       1406                53       2014                12        456                 39        1482                9         342                 6.91          0.359         1.61          17.8
  P56                --                        840          69         20         7          2          580          33       191                 67       388                 57        330                 10        58                  0         0                   ND            ND            ND            ND
  P57                *RAG1*                    2630         69.2       10         14         6          263          1        3                   18       47                  16        42                  3         8                   80        210                 8.29          0.239         2.1           56

*ND, no data; "--,"No mutation identified; OS, Omenn syndrome; WBC, White blood cell; P, polymorphonuclear neutrophils; L, lymphocytes; M, Monocytes; E, Eosinophils; B, basophils; Plt, Platelets; ALC/ul, absolute lymphocyte counts/uL; Th, T Helper cells; Tc, t cytotoxic cells; IgG, immunoglobulin G; IgA, immunoglobulin A; IgM, immunoglobulin M; IgE, immunoglobulin E; IL2RG, Interleukin 2 receptor gamma chain; JAK3, Janus Kinase 3; IL7RA, Interleukin 7 receptor alpha; ADA, Adenosine Deaminase; PNP, Purine nucleoside phosphorylase; AK2, adenylate kinase 2; RAG1/2, Recombination activating gene1/2; DCLER1C, DNA Cross-Link Repair 1C; RFXAP, Regulatory Factor X Associated Protein; RFX5, Regulatory factor 5; RFXANK, Regulatory Factor X Associated Ankyrin Containing Protein); CIITA, Class II Major Histocompatibility Complex Transactivator; ZAP70, Zeta-chain-associated protein kinase 70*.

Absent HLA-DR expression was noted in 6 of 57 patients and they were classified as MHC class II deficient cases. Elevated HLA-DR expression with other features of Omenn SCID such as skin rash, hepatosplenomegaly, elevated eosinophil counts was identified in 4 patients. T cell proliferation assay was performed in 3 leaky SCID patients and all had a poor T cell response to PHA.

The median percentage of naïve Th cells(0.3 \[range, 0--8\]%) within the typical and atypical SCID patient group was significantly lower than the median percentage of healthy age matched control group 73% (\[range, 66--89\]%; *p* \< 0.0001).The median percentage of naïve Tc cells was significantly lower in SCID group than control group (7 \[range, 0--29\] vs. 64\[range, 41--74\]; *p* \< 0.001). In MHC class II deficiency cases, a selective deficiency of naïve cells on CD4 cells was noted in 3 of 4 cases. The median percentage of naïve Th in MHC class II deficient cases was 39.50 (range, 29--48) which was significantly lower than the median percentage of healthy control group 77 (\[range, 66--99\]; *p* \< 0.003). The naïve Tc percentage was within the normal ranges in these 3 cases. Measurement of naïve T cell percentages in one case of ZAP70 deficiency revealed reduction of naïve T cell subsets on both CD4 and CD8.

Four patients with T^−^B^−^NK^−^ and 1 patient with T^+^B^−^NK^−^ had RBC-ADA activity (≤0.5 U/g Hb) lower than the healthy controls (1.1--2.5 U/g Hb) and were sequenced for *ADA* gene defects.

Absent CD132 expression on B cells was observed in 6 patients and they were classified as X-SCID. Seven patients with B^+^ phenotype had detectable T cells and could be tested for JAK3-pSTAT5 signaling studies and CD127 expression. Of these, 2 patients (P12,39) had absent pSTAT5 expression on T cells after IL-2 stimulation and two patients (P12, P44) had reduced expression of CD127 on T cells.

Analysis of T cell receptor excision circles (TRECs) was done in all the SCID and CID patients and compared with TREC copies in age matched healthy controls samples (*n* = 55). The median TREC copies in T^−^B^+^ SCID (2.3\[0.0175--16\]) and T^−^B^−^ SCID (3\[0--11\]) was significantly lower than the control group (139 copies \[range, 62--348\]; *p* \< 0.0001). The median TREC copies in MHC class II deficiency 81.5(13--154) and ZAP70 deficiency 40.5(17--64) were significantly higher than SCID patients (*p* \< 0.01).

Treatment and Outcome
---------------------

Intravenous immunoglobulin was administered to 75% of the patients and 54% of patients were on prophylaxis (antibacterial, antiviral, and antifungal). During the study period, 4 patients (P6, P12, P13, P20) underwent HSCT however, had a poor survival outcome. The median age at transplant was 8 months (range, 2--12). P6 underwent umbilical cord blood transplant and died due to post-transplant complications like diarrhea and Gram-negative sepsis. P12 and P13 underwent haploidentical HSCT, however expired from Graft vs. Host disease and adenovirus infection, respectively. P20 underwent HSCT from HLA identical sibling, however, expired in the period immediately followed by HSCT due to lung damage and systemic candidiasis. P6 and P20 underwent HSCT using myeloablative conditioning (Treosulfan, Cyclophosphamide, anti-thymocyte globulin \[ATG\]). For the other two patients, no details were available on the conditioning regimen.

Of the remaining patients, 49 patients could be followed up. Presently, only 6 patients are surviving. These patients were recently diagnosed as SCID and the median age of these children is 5.5 months (range, 2--30). The patient aged 2.5 years (30 months) had a late onset of presentation (2 years). At the time of last available report, 2 of these 6 patients were awaiting a transplant.

The median age of death in patients who did not undergo HSCT (*n* = 43) was 6 months (range, 1.5 months−3 years). Majority of these children expired before 12 months of age (*n* = 38). Three patients survived beyond 1 year of age (Patient P1 with PNP deficiency, P5 with ZAP70 deficiency and P26 with hypomorphic *RAG* gene mutation). While P1 and P5 expired within 2 years of age, P26 expired at 3 years. The main cause of death in all the patients was respiratory failure, chronic diarrhea, sepsis and disseminated BCG in 1 patient.

Molecular Findings
------------------

As a first-line approach, molecular investigations were done in the patients by sanger sequencing of the common genes like *IL2RG, IL7RA, ADA, RAG1, RAG2, ZAP70* gene depending on the immunophenotypic pattern. Twenty-five patients could be molecularly characterized using this approach. In a quest to identify the underlying genetic defect in the remaining cases, Targeted Next Generation sequencing (T-NGS)- Primary immunodeficiency (PID) panel was done (*n* = 32). Of the 32 cases referred for T-NGS, 24 cases could be molecularly characterized, however, 8 cases still remained uncharacterized.

Overall, a total of 49 patients could be molecularly characterized in this study. Of the 25 cases characterized by sanger sequencing, we identified 7 patients with mutations in *IL2RG*, 1 patient with *IL7Ra* deficiency, 5 with *ADA* deficiency, 1 with *PNP* defect, 1 with *AK2* defect,9 patients with *RAG1/2* deficiency and 1 case of *ZAP70* defect. With the help of T-NGS, genetic cause could be identified in 24 cases with 9 cases of *JAK3* deficiency (^\*^1 case was identified with whole exome sequencing), 6 MHC class II deficient cases, 3 *RAG* 1/2mutations, 2 *IL2RG* defects, 1 *PRKDC* defect, 2 cases of *DCLER1C*, an atypical case of ZAP70 deficiency. The nature of novel missense mutations identified in our cohort was determined by *in silico* tools like Mutation Taster ([@B10]), SIFT ([@B11]) and Polyphen-2 ([@B12]). Depending on the availability of parent\'s sample, familial segregation analysis was performed.

The molecular findings are presented in [Tables 3](#T3){ref-type="table"}--[7](#T7){ref-type="table"}.

###### 

Molecular findings in T^−/+^B^+^NK^−^SCID.

  **Pt No**.   **Defective gene**                        **Nucleotide change**        **Protein change**                  **Mutation type**                **Allele**              **Carrier status**   **References**   **Method**               
  ------------ ----------------------------------------- ---------------------------- ----------------------------------- -------------------------------- ----------------------- -------------------- ---------------- ------------------------ --------
  P7           *IL2RG*                                   c.202 G\>A                   p\. E68K                            Missense                         Hemizygous              Carrier              NA               ([@B13])                 Sanger
  P8           *IL2RG*                                   c.202 G\>A                   p\. E68K                            Missense                         Hemizygous              Carrier              NA               ([@B13])                 Sanger
  P10          *IL2RG*                                   c.943 A\>T                   p\. K315X                           Nonsense                         Hemizygous              Carrier              NA               This study               Sanger
  P12          *JAK3*[^\*^](#TN1){ref-type="table-fn"}   c.2072T\>A                   p\. V691E                           Missense                         Homozygous              Carrier              Carrier          This study               NGS
  P15          *JAK3*                                    c.2978G\>A                   p\. W993X                           Nonsense                         Homozygous              Carrier              Carrier          This study               NGS
  P25          PRKDC                                     c.9862C\>T c.11588G\>A       p\. R3288W, p. R3863H               Missense Missense                Compound Heterozygous   ND                   ND               This study               NGS
  P29          *JAK3*                                    c.2488A\>T                   p\. K830X                           Nonsense                         Homozygous              Carrier              Carrier          This study               NGS
  P36          *JAK3*                                    c.595 C\>T, c.2805^+^5G\>A   p\. R199C 5′proximal splice site    Missense, Splice site mutation   Compound Heterozygous   Carrier              Carrier          Reported This study      NGS
  P37          *IL2RG*                                   c.676C\>T                    p\. R226C                           Missense                         Hemizygous              ND                   ND               ([@B13])                 NGS
  P39          *JAK3*                                    c.862-2A\>G, c.442 G\>A      3′ Splice site Intron 6; p. G148R   Splice site Missense             Compound Heterozygous   Carrier              Carrier          This study, This study   NGS
  P40          *JAK3*                                    c.2243delA                   p\. K748SfsTer8                     Deletion                         Homozygous              Carrier              Carrier          This study               NGS
  P45          *IL2RG*                                   c.3 G\>A                     p\. M1I                             Frameshift                       Hemizygous              ND                   ND               ([@B13])                 Sanger
  P31          *IL7RA*                                   c.437_438delTT               p\. F146CfsTer5                     Frameshift                       Homozygous              Carrier              Carrier          This study               Sanger
  P41          *IL2RG*                                   c.53delT                     p\. L18RfsTer6                      Frameshift                       Hemizygous              ND                   ND               This study               Sanger
  P44          *IL2RG*                                   c.979G\>A                    p\. E327K                           Missense                         Hemizygous              Carrier              ND               This study               Sanger
  P52          *JAK3*                                    c.2350 G\>C                  p\. R784N                           Missense                         Homozygous              Carrier              Carrier          ([@B14])                 NGS
  P54          *JAK3*                                    c.1351 C\>T                  p.R451X                             Nonsense                         Homozygous              Carrier              Carrier          This study               NGS
  P55          *JAK3*                                    c.307 C\>T c.421-6 C\>T      p.R103C; 3′splice variant           Missense, Splice site            Compound Heterozygous   ND                   ND               ([@B15]) This study      NGS

IL2RG, Interleukin 2 receptor gamma chain; JAK3, Janus Kinase 3; IL7RA, Interleukin 7 receptor alpha;

*P12 was identified with the help of WES*.

###### 

Molecular findings in T^−/+^B^+^NK^+^SCID.

  **Pt No**.   **Defective gene**   **Nucleotide change**   **Protein change**   **Mutation type**   **Allele**              **Carrier Status**       **Reference**            **Method**   
  ------------ -------------------- ----------------------- -------------------- ------------------- ----------------------- ------------------------ ------------------------ ------------ --------
  P26          *RAG1*               c.2849delT              p\. I950Mfster28     Deletion            Compound heterozygous   Carrier for c.2849delT   Carrier for c.1421G\>A   This study   NGS
                                    c.1421G\>A              p\. R474H            Missense                                                                                      ([@B16])     
  P9           *IL2RG*              c.749 del C             T250Ifster23         Frameshift          Hemizygous              NA                       NA                       This study   Sanger

*RAG1, recombination activating gene1; IL2RG, Interleukin 2 receptor gamma chain*.

###### 

Molecular findings in T^−/+^B^−^NK^−^SCID.

  **Pt No**.   **Defective gene**   **Nucleotide change**   **Protein change**   **Mutation type**   **Allele**              **Carrier status**   **References**   **Method**    
  ------------ -------------------- ----------------------- -------------------- ------------------- ----------------------- -------------------- ---------------- ------------- --------
  P1           *PNP*                c.199C\>T               p.67R\>X             Nonsense            Homozygous              Carrier              Carrier          This study    Sanger
  P4           *ADA*                c.42 T\>C               p\. L14P             Missense            Homozygous              Carrier              Carrier          This study    Sanger
  P11          *ADA*                c.523 C\>T              p.Q175 X             Nonsense            Homozygous              Carrier              Carrier          This study    Sanger
                                    c.716 G\>A              p\. G239D            Missense            Homozygous              Carrier              Carrier          ([@B17])      Sanger
  P13          *AK2*                c.276 C\>A              p.C92X               Nonsense            Homozygous              ND                   ND               This study    Sanger
  P14          *ADA*                c.3632A\>G.             3′ splice variant    Splice site         Compound Heterozygous   Carrier              Carrier          This study    Sanger
                                    c.613_615del            p\. Val205del        Deletion                                                                          This study    
  P22          *ADA*                c.523 C\>T c.716 G\>A   p.Q175 X             Missense            Homozygous              Carrier              Carrier          This study,   Sanger
                                                            p\. G239D                                                                                              ([@B17])      
  P53          *ADA*                c.716 G\>A              p\. G239D            Missense            Homozygous              Carrier              Carrier          ([@B17])      Sanger
  P48          *RAG1*               c.2146C\>T              p\. R716W            Missense            Homozygous              Carrier              Carrier          ([@B16])      NGS
  P17          IL2RG                c.331delA               p\. I111SfsTer36     Frameshift          Hemizygous              Carrier              NA               This study    Sanger

*ADA, Adenosine Deaminase; PNP, Purine nucleoside phosphorylase; AK2, adenylate kinase 2*.

###### 

Molecular findings in T^−/+^B^−^NK^+^SCID.

  **Pt No**.   **Defective gene**   **Nucleotide change**   **Protein change**   **Mutation type**   **Allele**              **Carrier status**   **References**   **Method**   
  ------------ -------------------- ----------------------- -------------------- ------------------- ----------------------- -------------------- ---------------- ------------ --------
  P2           *RAG1*               c.994C\>T               p\. R331X            Nonsense            Homozygous              Carrier              Carrier          This study   Sanger
  P18          *RAG2*               c.698G\>T               p\. G35V             Missense            Homozygous              Carrier              Carrier          ([@B18])     Sanger
  P24          *RAG2*               c.1321C\>T              p\. P441S            Missense            Homozygous              ND                   Carrier          This study   Sanger
  P32          *DCLRE1C*            c.879G\>A               p\. W293X            Nonsense            Homozygous              ND                   ND               This study   Sanger
  P35          *RAG2*               c.171delG,              p.K58STer73,         Frameshift          Compound Heterozygous   Carrier              Carrier          This study   Sanger
                                    c.104 G\>C              p\. G35A             Missense                                                                          ([@B18])     
  P38          *RAG1*               c.1201_1216del          p.S401LfsTer6        Frameshift          Homozygous              Carrier              Carrier          This study   Sanger
  P42          *RAG1*               c.2146C\>T              p\. R716W            Missense            Homozygous              Carrier              Carrier          ([@B16])     NGS
  P43          *RAG2*               c.1247G\>T              p.W416L              Missense            Homozygous              Carrier              Carrier          ([@B19])     Sanger
  P46          *DCLER1C*            Del Exon 1-3            NA                   Deletion            Homozygous              ND                   ND               ([@B15])     NGS
  P51          *RAG1*               c.437_438delAG          p.R147SfsTer21       Deletion            Homozygous              Carrier              Carrier          This study   NGS
  P57          *RAG1*               c.619 G\>A              p.W151X              Nonsense            Homozygous              ND                   Carrier          This study   Sanger
  P16          *RAG1*               c.1441 G\>A             p.R474H              Missense            Compound Heterozygous   ND                   ND               This study   NGS
                                    c.1442 G\>A             P.T481C              Missense                                                                          ([@B19])     

*RAG1/2, Recombination activating gene1/2; DCLER1C, DNA Cross-Link Repair 1C*.

###### 

Molecular findings in CID.

  **Pt No**.   **Defective gene**   **Nucleotide change**   **Protein change**   **Mutation type**   **Allele**   **Carrier status**   **References**   **Method**   
  ------------ -------------------- ----------------------- -------------------- ------------------- ------------ -------------------- ---------------- ------------ --------
  P3           *RFXAP*              c.460_461insC           p\. K155QfsTer21     Frameshift          Homozygous   Carrier              Carrier          ([@B20])     NGS
  P6           *RFXAP*              c.460_461insC           p\. K155QfsTer21     Frameshift          Homozygous   Carrier              Carrier          ([@B20])     NGS
  P20          *RFX5*               c.1154delT              L385YfsTer33         Frameshift          Homozygous   Carrier              Carrier          ([@B20])     NGS
  P21          *RFXAP*              c.709-1G\>T             Intron 2             Splice site         Homozygous   Carrier              Carrier          ([@B20])     NGS
  P33          *CIITA*              c.2436C\>A              p\. C812X            Nonsense            Homozygous   ND                   ND               ([@B20])     NGS
  P49          *RFXANK*             c.378_387del            p\. P127GfsTer74     Frameshift          Homozygous   ND                   ND               ([@B20])     NGS
  P5           *ZAP70*              c.183 T\>A              p\. RIle61N          Missense            Homozygous   Carrier              Carrier          ([@B21])     Sanger
  P50          *ZAP70*              c.847C\>T               p\. R283X            Nonsense            Homozygous   Carrier              Carrier          This study   NGS

*RFXAP, Regulatory Factor X Associated Protein; RFX5, Regulatory factor 5; RFXANK, Regulatory Factor X Associated Ankyrin Containing Protein); CIITA, Class II Major Histocompatibility Complex Transactivator; ZAP70, Zeta-chain-associated protein kinase 70*.

Discussion {#s4}
==========

SCID is a genetically heterogenous group of disorders that affects both the cellular and humoral immunity. The incidence and prevalence of SCID varies in different parts of the world and is reported to be higher in countries with a high rate of consanguinity. To the best of our knowledge, this is the first comprehensive report on clinical, immunological, and molecular studies in 57 SCID patients from India.

Majority of our patients (89%) presented within 6 months of age with a median age of onset of 2 months. The median age of diagnosis in our cohort (152 days; 5 months) was consistent with other studies such as Canada (4.2 months), China (5 months), Greece (6 months), and United States (6.59 months) ([@B22]--[@B24]). Patients with MHC class II deficiency and ZAP70 deficiency were also referred to us within 1 year of age with a clinical suspicion of SCID. Though, these groups are categorized under "Combined immunodeficiency less profound than Severe combined immunodeficiency" our patient data highlights the clinical severity of these disorders to be like SCID.

We observed 36% rate of consanguinity in our cohort which is intermediate to countries like Iran, Kuwait ([@B18]) where a very high rate of consanguinity (77%) exists and UK which has 3% rate of consanguineous marriages ([@B23]).

Lymphopenia, which is considered as a hallmark of SCID was observed in 67% of our patients (cut off \<2,500 counts/μL). The patients with normal ALC/μl included B^+^ SCIDs (*n* = 10) and Omenn SCID (*n* = 4). MHC class II deficient patients and ZAP70 deficient patients also had normal ALC/μl. This is consistent with a study from china where 86% of the patients had a low lymphocyte count ([@B25]). Pilot series from United States identified most newborns with SCID based on ALC, but, 10% of SCID samples had normal lymphocyte counts.

The median TREC copies/μL were significantly lower in SCID patients as compared to healthy controls. Importantly, we found TREC copies to be higher than typical SCIDs in children with either CD4 or CD8 lymphopenia. Both TREC copies and ALC/μL are higher in MHC class II deficiency and ZAP70 deficiency than typical SCIDs. Hence, in a scenario of severe infections with normal ALC/μL and normal TRECs, extensive immunological evaluations should still be performed to rule out these forms of SCID. An important clue to underlying immunodeficiency in both these cases were reduced percentages of naïve Th/Tc which was evaluated in 4 cases of MHC class II deficiency and 1 case of ZAP70 deficiency. Notably, 3 of 4 MHC class II deficiency cases showed a selective reduction of Naïve Th population with normal percentages of naive Tc cells. Hence, a suspicion of MHC class II deficiency can be made in a scenario of selective reduction of naïve Th subset.

Traditionally SCID patients have been classified based on absolute counts of T, B, NK cells. Majority of our cases belonged to the category of T^−^B^−^ SCID (39%) followed by T^−^B^+^ SCID (28%). In Greece, 40% SCID patients belonged to T^−^B^−^NK^+^ category and in Serbia and Montenegro, 57% patients with SCID and Omenn syndrome presented with T^−^B^−^NK^+^ SCID phenotype ([@B26]). In the registry of Saudi Arabia for combined immunodeficiencies, T^−^B^−^ was the most common type; 17% followed by T^−^B^+^ found in 5% and Omenn syndrome in 3.6% ([@B26]). China\'s SCID registry has reported 66.7% of patients with B^+^ SCID and 7.1% of the cohort with B^−^ SCID ([@B25]). Defective expression of major histocompatibility complex class II (MHC) molecules accounted for 5% of severe combined immunodeficiency (SCID) in Canadian Survey and almost 20--30% of SCID cases in Kuwait and North Africa ([@B27]). MHC class II deficiency accounted for 10.5%and ZAP70 deficiency constituted 3.5% of our patient group.

The pattern of lymphocyte subsets serves as a useful guide to perform genetic studies, however, molecular diagnosis of SCID is highly challenging due to the involvement of multiple genes whose defect can result in same immunophenotypic pattern. Hence, in such cases DNA sequencing of individual genes becomes tedious, time consuming and expensive. As there exists a significant clinical and immunophenotypic overlap between different genetic subtypes of SCID, we performed assays like measurement of RBC-ADA levels, flow cytometric evaluation of HLA-DR, CD132, CD127, and pSTAT5 expression to narrow down the list of possible genetic defects.

Spectrophotometric estimation of RBC-ADA levels was found to be a simple, cost- effective and accurate method for identification of ADA deficient patients. Five patients had low RBC-ADA levels and were also detected with a molecular defect in the *ADA* gene. Of the remaining patients with T^−^B^−^NK^−^ phenotype (*n* = 6), a *PNP* and *AK2* defect were identified. No pathogenic variant was identified in 2 patients despite T-NGS. In the remaining two patients, mutations were identified in *IL2RG* and *RAG1* gene. These findings expand the phenotypic spectrum of typical X-SCID and RAG SCID.

Study of HLA-DR expression on immune cells helped in identification of MHC class II deficient patients (absent HLA-DR expression) and Omenn SCID (elevated HLA-DR expression suggesting activated T lymphocytes).

Absent/reduced expression of CD132 on B cells helped identify 6 patients (67%) with *IL2RG* gene defect. One patient with c.676 C\>T in Exon 5 of *IL2RG* had a normal expression of CD132 on B cells (89%) suggesting this mutation did not affect the protein expression. Functional screening of STAT3 phosphorylation after IL-21 stimulation to assess the functionality of γchain could have helped us in this scenario, but this assay was not performed in our study.

Two patients with T^+^B^+^ phenotype were identified with *RAG1/2* and *PRKDC* gene defect suggesting these mutations to be hypomorphic thereby, producing residual number of T and B cells. The oligoclonality of TCR-Vβ repertoire was tested in the RAG deficient patient and was found to be clonally restricted (Vβ13.1 on CD4^+^T cells \[20.5%\] and Vβ11\[5%\], Vβ16 \[4.1%\] on CD8^+^T cells). A case of *IL7RA* gene defect was detected in a patient with T^−^B^+^NK^−^ phenotype. CD127 expression studies could not be performed in the patient due to lack of T cells.

We observed reduced CD127 expression in 2 patients (P12 and P44) who were later identified with a mutation in *JAK3* gene and *IL2RG* gene, respectively. The possible explanation for this observation lies in the mechanism of IL7Ra receptor downregulation/ internalization due to high circulating levels of IL7 in some lymphopenic patients. However, studies to look for internalized CD127 or western blot from separated T cells to look for CD127 expression could not be performed in our study. Hence, a reduced CD127 expression on flow cytometry needs to be interpreted carefully.

A hemizygous deletion (c.749 del C) in Exon 5 of *IL2RG* gene leading to frameshift mutation was identified in a T^−^B^+^NK^+^ patient (male). This patient had a normal CD132 expression on B cells, but its functionality was not tested. Normal NK cell numbers in γchain deficient patients have been reported earlier ([@B28]) and they are predicted to be of maternal origin. In patients with mutations involving the γc portion of the *IL2RG*, normal NK cell numbers have been identified and these observations have raised the possibility of a potential downstream activation mechanism in NK cell differentiation ([@B28]).

Flow cytometric evaluation of proteins specifically expressed on T cells (for e.g.,: CD127) or assays that required TCR engagement with specific stimulants (JAK3-pSTAT5) could not be assessed in patients who lacked T cells. Almost 65% of our B^+^ SCID cohort had absent T cells hence, both CD127 and phospho-STAT5 assay had a limited utility in our study and we had to rely on genetic analysis to identify the defect.

The frequency of mutations in *RAG1/2* (21 %) in the current study is like United States (21%) and the Netherlands (32%), but much less compared to Greece (41%) and Serbia (61%) where a common founder gene defect in RAG1 is likely ([@B18]). A patient with microcephaly, flat nasal bridge, short philtrum was suspected of a defect in DNA Ligase IV ([@B1]) but was identified with a *RAG1* defect. Three patients within this group were classified as Omenn SCID (2 *RAG1* mutations and 1 *RAG2* mutation).

The molecular findings in five cases of MHC class II deficiency from our cohort has been recently described ([@B20]). Additionally, we have identified another patient with a defect in *RFXANK* gene. There have been only 2 patients with confirmed *RFXANK* mutations reported in Asia. *RFXANK* mutation causes bare lymphocyte syndrome type 2B ([@B15]) commonly observed in North Africa ([@B15]) and in other places such as France and Spain.

An atypical case of ZAP70 deficiency with a novel nonsense mutation in *ZAP70* gene was identified in 1 patient with elevated CD8^+^T cells. Poor proliferative responses was the only clue to an underlying immunodeficiency in this patient. Unfortunately, we could not assess the intracellular ZAP70 expression or assess the TCR-Vβ repertoire on CD4 and CD8 T cells as the child expired by the time of receiving a molecular diagnosis. This mutation further extends the phenotypic spectrum of ZAP70 deficiency.

The spectrum of genetic defects in our cohort revealed a wide genetic heterogeneity with 21% *RAG1/2* defects,15.8% *IL2RG* defects, 15.8% *JAK3* defect, 1.7% *IL7RA* defect, 8.8% *ADA* defect, 1.8% *AK2* defect, 1.8% *PNP* defect, 3.5% *DCLER1C* defect, 1.8% *PRKDC* defect, 10.5% with MHC class II deficiency and 3.5% *ZAP70* defects. Thirty-two novel variants were identified in our study and no founder mutation was detected in our cohort. 14% of the defects still remained uncharacterized despite application of T-NGS (list of genes covered in the T-NGS panel is presented in [Table 8](#T8){ref-type="table"}) and it would be interesting to perform whole exome/genome sequencing in these cases as that may lead to discovery of novel genetic defects causing SCID (no pathogenic variant explaining the cause of immunodeficiency could be identified in one patient \[P47\] even after WES). Our data also shows a lack of demonstrable correlation between genotype and phenotype in few cases (7%). Certain genetic and environmental factors, concurrent mutations in other SCID genes, modifier gene(s), and mutations, that lead to sparing or disrupting developments of other lineages of lymphocytes may be the cause for lack of correlation ([@B15]).

###### 

Genes covered in Targeted NGS panel.

  ---------- ----------- ----------- ----------- ----------- ----------- ------------- ------------- -----------
  *ACP5*     *ACTB*      *ADA*       *IFNAR2*    *IFNGR1*    *IFNGR2*    *RNASEH2A*    *RNASEH2C*    *TRAC*
  *ADAM17*   *ADAR*      *AICDA*     *IGHM*      *IGKC*      *IGLL1*     *RNF168*      *RNU4ATAC*    *TREX1*
  *AIRE*     *AK2*       *AP1S3*     *IKBKB*     *IKZF1*     *IL10*      *RORC*        *RTEL1*       *TTC7A*
  *AP3B1*    *AP3D1*     *APOL1*     *IL10RA*    *IL10RB*    *IL12B*     *SAMD9*       *SAMHD1*      *UNC93B1*
  *ATM*      *ATP6AP1*   *B2M*       *IL12RB1*   *IL17F*     *IL17RA*    *SBDS*        *SERPING1*    *USP18*
  *BCL10*    *BCL11B*    *BLM*       *IL17RC*    *IL1RN*     *IL21R*     *SH2D1A*      *SLC29A3*     *WAS*
  *BLNK*     *BTK*       *C1QA*      *IL2RA*     *IL2RG*     *IL36RN*    *SLC35C1*     *SLC46A1*     *WRAP53*
  *C1QB*     *C1QC*      *C1R*       *IL7R*      *INO80*     *IRAK1*     *SMARCAL1*    *SNX10*       *ZBTB24*
  *C1S*      *C2*        *C3*        *IRAK4*     *IRF2BP2*   *IRF3*      *SP110*       *STAT1*       
  *C5*       *C6*        *C7*        *IRF7*      *IRF8*      *ISG15*     *STAT2*       *STAT5B*      
  *C8A*      *C8B*       *C8G*       *ITCH*      *ITGB2*     *ITK*       *STIM1*       *STK4*        
  *C9*       *CARD11*    *CARD14*    *JAGN1*     *JAK1*      *JAK3*      *STXBP2*      *STX11*       
  *CARD9*    *CASP10*    *CASP8*     *KDM6A*     *KMT2D*     *LAMTOR2*   *TAPBP*       *TAP2*        
  *CCBE1*    *CD19*      *CD247*     *LAT*       *LCK*       *LIG1*      *TBX1*        *TBK1*        
  *CD27*     *CD3D*      *CD3E*      *LIG4*      *LPIN2*     *LRBA*      *TCN2*        *TCIRG1*      
  *CD3G*     *CD40*      *CD40LG*    *LYST*      *MAGT1*     *MALT1*     *TFRC*        *TERT*        
  *CD46*     *CD55*      *CD59*      *MAP3K14*   *MASP2*     *MCM4*      *TINF2*       *TICAM1*      
  *CD79A*    *CD79B*     *CD81*      *MEFV*      *MKL1*      *MOGS*      *TMC6*        *TLR3*        
  *CD8A*     *CDCA7*     *CEBPE*     *MS4A1*     *MSH6*      *MSN*       *TNFAIP3*     *TMEM173*     
  *CECR1*    *CFB*       *CFD*       *MTHFD1*    *MVK*       *MYD88*     *TNFRSF13C*   *TNFRSF13B*   
  *CFH*      *CFHR1*     *CFHR2*     *MYSM1*     *NBAS*      *NBN*       *TNFSF11*     *TNFRSF4*     
  *CFHR3*    *CFHR4*     *CFHR5*     *NCF2*      *NCF4*      *NCSTN*     *TPP2*        *TPP1*        
  *CFI*      *CFP*       *CFTR*      *NDNL2*     *NFAT5*     *NFKB1*     *TRAF3IP2*    *TRAF3*       
  *CHD7*     *CIITA*     *CLCN7*     *NFKB2*     *NFKBIA*    *NHEJ1*     *TTC37*       *TRNT1*       
  *CLPB*     *COPA*      *CORO1A*    *NHP2*      *NLRC4*     *NLRP1*     *UNC13D*      *TYK2*        
  *CR2*      *CSF2RA*    *CSF2RB*    *NLRP12*    *NLRP3*     *NOD2*      *USB1*        *UNG*         
  *CSF3R*    *CTC1*      *CTLA4*     *NOP10*     *OBFC1*     *ORAI1*     *VPS45*       *VPS13B*      
  *CTPS1*    *CTSC*      *CXCR4*     *OSTM1*     *OTULIN*    *PARN*      *WIPF1*       *WDR1*        
  *CYBA*     *CYBB*      *DCLRE1C*   *PEPD*      *PGM3*      *PIK3CD*    *ZAP70*       *XIAP*        
  *DDX58*    *DKC1*      *DNAJC21*   *PIK3R1*    *PLCG2*     *PLEKHM1*   *RNASEH2B*    *TAP1*        
  *DNMT3B*   *DOCK2*     *DOCK8*     *PMS2*      *PNP*       *POLA1*     *RNF31*       *TAZ*         
  *ELANE*    *EPG5*      *ERCC6L2*   *POLE*      *POLE2*     *PRF1*      *RPSA*        *TCF3*        
  *EXTL3*    *FAAP24*    *FADD*      *PRKCD*     *PRKDC*     *PSEN1*     *SAMD9L*      *TERC*        
  *FAS*      *FASLG*     *FAT4*      *PSENEN*    *PSMB8*     *PSTPIP1*   *SEMA3E*      *THBD*        
  *FCGR3A*   *FCN3*      *FERMT3*    *PTEN*      *PTPRC*     *RAB27A*    *SH3BP2*      *TIRAP*       
  *FOXN1*    *FOXP3*     *FPR1*      *RAC2*      *RAG1*      *RAG2*      *SLC37A4*     *TMC8*        
  *G6PC3*    *G6PD*      *GATA2*     *RANBP2*    *RASGRP1*   *RBCK1*     *SMARCD2*     *TNFRSF11A*   
  *GFI1*     *HAX1*      *HELLS*     *RFX5*      *RFXANK*    *RFXAP*     *SPINK5*      *TNFRSF1A*    
  *HMOX1*    *ICOS*      *IFIH1*     *RHOH*      *RLTPR*     *RMRP*      *STAT3*       *TNFSF12*     
  ---------- ----------- ----------- ----------- ----------- ----------- ------------- ------------- -----------

The autosomal recessive form of SCID (86%) was more common than X-SCID (14%) in our cohort. This is in contrast with several studies that reported a predominance of X-linked SCID which accounts for approximately half of SCID cases ([@B24]). This finding supports that genetic defects in SCID patients probably differ depending on diverse genetic backgrounds. Our data is similar to countries where consanguinity is practiced like in Turkey where the AR form accounts for 80% SCID cases ([@B29]) as compared to data from USA with AR form 20% and a low rate of consanguinity ([@B23]).

The overall outcome in our cohort is extremely poor with death occurring in 92% of the patients. Only 4 patients underwent HSCT, and none of them could survive the transplant. The median age at HSCT in our cohort was 7.5 months. It is well known that HSCT for (S)CID before the age of 3.5 months results in a superior outcome ([@B6]). One of our patients with MHC class II deficiency (P7) had a pre-symptomatic diagnosis and received an early transplant (at 3 months), however, he expired within 8 days of transplant due to severe diarrhea and gram-negative sepsis. As stated in a recent report, the reason for low survival rate in MHC class II deficiency patients may be due to presentation of donor antigens by donor antigen-presenting cells to recipient T cells leading to graft rejection ([@B30]).

We consider delayed diagnosis as the major cause for a poor survival outcome in our cohort. Our data is consistent with countries where newborn screening (NBS) for SCID has not yet been implemented ([@B18]). Without NBS, asymptomatic diagnosis for SCID is possible only in a scenario of strong family history. In several other cases, even before the child is diagnosed as SCID and the crucial decision for transplantation is taken, the child has significant number of infections which affects the survival outcome. Maintenance on IVIg therapy is expensive and a major constraint in the management of children with PIDs in India, as also in other developing countries ([@B31]). Only two state governments (Punjab and Karnataka) in India have taken a major policy initiative to provide IVIg freely to the patients. In the other states, several children are not privileged to get the recommended dose of IVIg ([@B31]). Many centers in India are now routinely performing HSCT for a variety of malignant diseases in both children and adults whose results are comparable to many international published reports ([@B32]), however, there is only a minority that have the requisite expertise for carrying out transplant for PIDs ([@B31]). A recent report by a tertiary referral center in India shared their 15-year experience of HSCT in children with PIDs with encouraging results of an overall survival rate of 62 and 55% survival rate for SCIDs ([@B33]). However, the number of such centers that specialize in transplantation for PIDs in India are very few and specific arrangements are needed to transfer the patients to centers in other states. Financial constraint is one of the major reasons for families to refuse transplantation. Overall, delayed diagnosis due to lack of awareness about SCID among the pediatricians, lack of expertise in HSCT for SCID, financial constraints and lack of a suitable donor are the reasons for such a poor survival rate observed in our cohort.

Prenatal diagnosis (PND) is hence, highly useful in families affected with SCID. The preferred procedure for prenatal diagnosis is genetic confirmation in the index case and parents and then performing PND by chorionic villus sampling or amniocentesis. This was helpful in two of our affected families (index case P5 and P6). Two families (index case P6 and P42) benefited from the facility of phenotypic prenatal diagnosis performed on cordocentesis sample at 18 weeks of gestation due to lack of genetic diagnosis at the time of PND.

Early detection of SCID and HSCT at a pre-symptomatic stage has proven to result in a better outcome in countries with NBS program for SCID and advanced health care systems. As NBS for SCID is not yet performed in our country, there exists a high chance that we are missing out many cases as these children may have expired before receiving a diagnosis. Pilot studies for NBS in our country could provide data on the true incidence of SCID in our population. Overall, our data reveals a wide genetic heterogeneity of SCID in the Indian population, confirms the poor prognosis of SCID due to delayed diagnosis and highlights the need for implementing NBS for SCID in India.
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